Open AccessComparison of Gd‐Bz‐TTDA, Gd‐EOB‐DTPA, and Gd‐BOPTA for dynamic MR imaging of the liver in rat models
Author(s) -
Jaw TweiShiun,
Chen ShihHsien,
Wang YunMing,
Hsu JuiSheng,
Kuo YuTing,
Chiu YenYu,
Tsai KunBow,
Hsieh TsyhJyi,
Liu GinChung
Publication year - 2012
Publication title -
the kaohsiung journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.439
H-Index - 36
eISSN - 2410-8650
pISSN - 1607-551X
DOI - 10.1016/j.kjms.2011.10.017
Subject(s) - hepatocellular carcinoma , gadoxetic acid , chemistry , lesion , nuclear medicine , magnetic resonance imaging , medicine , radiology , pathology , gadolinium dtpa
To evaluate the competitive potential of a new lipophilic paramagnetic complex, Gd‐Bz‐TTDA [4‐benzyl‐3,6,10‐tri (carboxymethyl)‐3,6,10‐triazado‐decanedioic acid] compared with two other commercially available MR hepatobiliary contrast agents, gadobenate dimeglumine (Gd‐BOPTA) and gadoxetic acid (Gd‐EOB‐DTPA), dynamic MR imaging studies were performed on normal and hepatocellular carcinoma (HCC) rat models using a 1.5‐Tesla MR scanner. The results indicate that normal rats that were injected with 0.1 mmol/kg Gd‐Bz‐TTDA showed significantly more intense and persistent liver enhancement than those that were injected with the same dose of Gd‐EOB‐DTPA or Gd‐BOPTA. All of these agents showed similar enhancement patterns in the implanted HCC. The liver‐lesion contrast‐to‐noise ratios were higher and more persistent in rats that were injected with Gd‐Bz‐TTDA. These results indicate that Gd‐Bz‐TTDA is comparable with the commercially available hepatobiliary agents, Gd‐EOB‐DTPA and Gd‐BOPTA, and can result in more intense and prolonged liver enhancement while still providing better liver‐lesion discrimination. These results warrant further large‐scale studies.